PIQUR to present posters on its lead compound PQR309 at AACR Annual Meeting 2015

Initial clinical results confirm that PQR309 is well tolerated and shows first signs of clinical antitumor activity

PIQUR Therapeutics AG today announced that the company and its academic collaborators will present five posters highlighting preclinical as well as clinical data on its lead compound, PQR309, at the American Association for Cancer Research (AACR) Annual Meeting, which will take place in Philadelphia, Pennsylvania, April 18-22, 2015. Initial results from the first-in-man phase 1 trial indicate that PQR309 is safe and well-tolerated with no significant side effects. “In addition to the good safety data, PQR309 has also shown the first encouraging signs of clinical activity in solid tumors. With these promising initial clinical results of PQR309, we are making an important step towards our vision to help patients to survive cancer”, commented Dr. Vladimir Cmiljanovic, CEO of PIQUR Therapeutics AG.

Following are the specifics of the abstracts, including session times and locations:

- “PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor” [Poster Session: PI3K Pathway and Metabolism Modulators, Abstract Number 2664, Mon, Apr 20, 1:00 - 5:00 PM, Location: Section 32, Poster Board Number 16]
- “PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability” [Poster Session: Pharmacokinetics and Pharmacodynamics, Abstract Number 4514, Tue, Apr 21, 1:00 - 5:00 PM, Poster Section 32, Poster Board Number 12]
- “First-in-man (FIM) pharmacodynamic (PD) and pharmacokinetic (PK) phase I trial of PQR309 in advanced solid tumors” [Poster Session: Phase I Clinical Trials, Abstract Number CT310, Tue, Apr 21, 8:00 AM - 12:00 PM, Poster Section 24, Poster Board Number 10]
- “Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas” [Poster Session: PI3K Pathway and Metabolism Modulators, Abstract Number 2652, Mon, Apr 20, 1:00 - 5:00 PM, Poster Section 32, Poster Board Number 4]
- “BKM120-mediated G2 arrest: Structural and functional segregation of off-target action and PI3K inhibition” [Poster Session: Signal Transduction Inhibitors, Abstract Number 671, Sun, Apr 19, 1:00 - 5:00 PM, Poster Section 28, Poster Board Number 15]
Helping patients to survive cancer
PIQUR aims to help patients to survive cancer. Two out of three people are now living at least five years after their cancer has been diagnosed. Despite of significant medical innovations in the treatment of cancer, there remains a high unmet medical need for therapies that not only prolong patients’ survival but also significantly improve quality of life. PIQUR targets both PI3K (phosphoinositide 3-kinase) and mTOR (mammalian target of rapamycin), two key signaling molecules that are vital to several essential biological processes, such as cell proliferation, survival and metastasis, making inhibition of the target attractive for cancer therapy.

PIQUR’s differentiation is the level of innovation with its unique, proprietary fragment and scaffold libraries, as well as cellular technology platforms, and their excellent products with novel, dual-acting ‘strong PI3K plus fine-tuned mTOR’ inhibitors that address the given challenges, meeting therapeutic, tolerance and galenic needs.

About PQR309
PIQUR’s lead compound, PQR309, is a potent and balanced pan-PI3K/mTOR inhibitor with excellent prospects to become a powerful anti-cancer drug. PQR309 compares favorably to current and clinically most advanced pan-PI3K/mTOR inhibitors with respect to the off-target effects and drug-like properties. Unlike most of its competitors, PQR309 crosses the blood-brain barrier, expanding its use beyond solid tumors and lymphomas and into brain cancers. PQR309 showed activity in different aggressive cancer cell lines inhibiting the PI3K/mTOR pathway. PIQUR has successfully concluded the first-in-man phase 1 study in Europe; the maximum tolerated dose (MTD) was determined and the results indicated first evidence of clinical antitumor activity. The full results of the phase 1 trial are anticipated in the second quarter of 2015 after completion of the ongoing expansion study in USA.

About PIQUR
PIQUR is a Swiss pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds. www.piqur.com

Media Relations:
Tatsuo Satoh
Head IT & Communications
T: +41 61 633 29 38
M: +41 78 819 17 44
tatsuo.satoh@piqur.com

Investor Relations:
Vladimir Cmiljanovic, PhD
Chief Executive Officer
T: +41 61 633 29 30
M: +41 76 516 87 72
vladimir.cmiljanovic@piqur.com

Daniel Piller
Partner IRF Communications
T: +41 43 244 81 54
daniel.piller@irfcom.ch